Gastroenteropancreatic Neuroendocrine Tumors
11 clinical trials · Condition
◉ Watch Gastroenteropancreatic Neuroendocrine Tumors
| Record | Firm | Date |
|---|---|---|
| Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (NCT04524442) | Advanced Accelerator Applications | 2021-01-25 |
| Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (NCT03043664) | Duke University | 2017-07-01 |
| [68 Ga]-DOTANOC PET/CT in GEP-NETs (NCT02608203) | Assistance Publique Hopitaux De Marseille | 2016-05-26 |
| Community-based Neuroendocrine Tumor (NET) Research Study (NCT02730104) | Ipsen | 2015-11-23 |
| Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (NCT02231762) | Ipsen | 2014-10-01 |
| Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs (NCT02630654) | Ipsen | 2014-03-24 |
| 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs (NCT01842165) | Jules Bordet Institute | 2013-05-01 |
Track Gastroenteropancreatic Neuroendocrine Tumors automatically
Every clearance here is in the API, with alerts when new ones post.